Featured Articles

  1. Fueling The Genetic Revolution With cGMP Manufacturing And Training 5/20/2022

    ElevateBio, in collaboration with Cytiva, is forging a path forward with a solution to de-risk the development of novel therapies, helping to speed the delivery of new CGTs and regenerative medicines.

  2. Lipid Nanoparticle Library For Non-Viral Delivery Of mRNA And saRNA Towards Vaccine And Cell & Gene Therapy Applications 4/18/2022

    Explore this proprietary ionizable lipid library which has shown promising potency towards various applications involving cell therapy, protein replacement therapy and RNA-based Vaccines.

  3. Novel Lipid Nanoparticle Delivery Reagent And Manufacturing Workflow 4/18/2022

    We aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.

  4. Scale-Up And Manufacturing Of Self-Amplifying RNA-LNPs 4/18/2022

    This poster shows the work to scale up COVID-19 self-amplifying RNA-Lipid nanoparticle using PNI developed ionizable lipid and formulation from 0.2, to 50 mg scale using PNI’s Manufacturing Platform.

  5. A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells For Off-The-Shelf Cancer Therapy 4/14/2022

    We report on the use of a novel lipid nanoparticle (LNP) reagent in a validated protocol to achieve successful complex gene editing in primary T cells with high efficiency while maintaining high cell viability.

  6. Accelerated Development Of Self-Amplifying mRNA (saRNA) Vaccines Using Microfluidics 4/14/2022

    We showcased the utility of microfluidics to enable low shear, rapid screening of preclinical candidates and the swift advancement to GMP-enabling studies.

  7. How Tools And Technologies Bring Advanced Therapies To Market 3/2/2022

    Gain insight into industry trends and the tools to support the development of RNA vaccines and therapeutics.

  8. Changing The Status Quo Of Vaccine Production 3/2/2022

    Learn how the mRNA technology behind COVID-19 vaccines is poised to disrupt the status quo to improve global vaccine manufacturing capabilities.

  9. Translation Of RNA Medicines From Design To Clinic 3/2/2022

    Understand the advantages and challenges of lipid-based delivery systems for successful translation of RNA into clinical development.

  10. Accelerating The Development And Scale-Up Of mRNA Vaccines 3/2/2022

    Learn how downstream considerations can make the difference between success and failure on the path towards the commercialization of mRNA vaccines.